SAN FRANCISCO (AP) _ Nektar Therapeutics (NKTR) on Wednesday reported second-quarter net income of $971.5 million, after reporting a loss in the same period a year earlier.

The San Francisco-based company said it had net income of $5.33 per share.

The results met Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was also for earnings of $5.33 per share.

The biopharmaceutical company posted revenue of $1.09 billion in the period, topping Street forecasts. Six analysts surveyed by Zacks expected $1.04 billion.

Nektar shares have fallen slightly more than 6 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $55.96, nearly tripling in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NKTR at https://www.zacks.com/ap/NKTR